Search Results - "Herzog, T. J."

Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option by Buechel, M., Herzog, T.J., Westin, S.N., Coleman, R.L., Monk, B.J., Moore, K.N.

“…Ovarian cancer remains the most deadly gynecologic cancer with the majority of patients relapsing within 3years of diagnosis. Traditional treatment paradigms…”
Get full text

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer by Vergote, I, du Bois, A, Floquet, A, Rau, J, Kim, J.-W, del Campo, J.M, Friedlander, M, Pignata, S, Fujiwara, K, Colombo, N, Mirza, M.R, Monk, B.J, Tsibulak, I, Calvert, P.M, Herzog, T.J, Hanker, L.C, Meunier, J, Lee, J.-Y, Bologna, A, Carrasco-Alfonso, M.J, Harter, P

“…AbstractObjectiveThe AGO-OVAR16 study was designed to test the efficacy, safety, and tolerability of pazopanib maintenance after first-line chemotherapy in…”
Get full text

Inclusion, diversity, equity, and access (IDEA) in gynecologic cancer clinical trials: A joint statement from GOG foundation and Society of Gynecologic Oncology (SGO) by Pothuri, B., Blank, S.V., Myers, T.K., Hines, J.F., Randall, L.M., O'Cearbhaill, R.E., Slomovitz, B.M., Eskander, R.N., Alvarez Secord, A., Coleman, R.L., Walker, J.L., Monk, B.J., Moore, K.N., O'Malley, D.M., Copeland, L.J., Herzog, T.J.

Get full text

Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters—patient-centered end points in trials of maintenance therapy by Friedlander, M., Rau, J., Lee, C.K., Meier, W., Lesoin, A., Kim, J.-W., Poveda, A., Buck, M., Scambia, G., Shimada, M., Hilpert, F., King, M.T., Debruyne, P., Bologna, A., Malander, S., Monk, B.J., Petru, E., Calvert, P., Herzog, T.J., Barrett, C., du Bois, A.

“…Health-related quality of life (HRQoL) was a secondary end point in AGO-OVAR 16, which randomized 940 patients with EOC after first-line chemotherapy to…”
Get full text

A clinical and radiographic variant of wernicke-korsakoff syndrome in a nonalcoholic patient by FLINT, A. C, ANZISKA, Y, RAUSCH, M. E, HERZOG, T. J, WILLIAMS, O

Get full text

Microsatellite Instability, MLH1 Promoter Methylation, and Loss of Mismatch Repair in Endometrial Cancer and Concomitant Atypical Hyperplasia by Horowitz, N., Pinto, K., Mutch, D.G., Herzog, T.J., Rader, J.S., Gibb, R., Bocker-Edmonston, T., Goodfellow, P.J.

“…Objective. MLH1 methylation is associated with the microsatellite instability (MSI) phenotype in endometrial cancer and atypical endometrial hyperplasia, a…”
Get full text

Frustrated two-photon creation via interference by Herzog, TJ, Rarity, JG, Weinfurter, H, Zeilinger, A

Get full text

Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers by PEIFFER, S. L, HERZOG, T. J, TRIBUNE, D. J, MUTCH, D. G, GERSELL, D. J, GOODFELLOW, P. J

“…Thirty-seven endometrial cancers were subjected to an allelotype analysis in an attempt to identify chromosomal regions that are lost in a significant portion…”
Get full text

Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer by Swisher, Elizabeth M., Mutch, David G., Rader, Janet S., Elbendary, Alaa, Herzog, Thomas J.

“…Objective:The purpose of this study was to define the response rate and toxicity of topotecan in patients with ovarian cancer resistant to first-line therapy…”
Get full text

The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer by Palayekar, M J, Herzog, T J

“…Epidermal growth factor receptor (EGFR) inhibitors are a new biologically targeted therapy, which may offer new hope in the treatment of patients with advanced…”
Get more information

Fallopian tube removal: "stic-ing" it to ovarian cancer: what is the utility of prophylactic tubal removal? by Herzog, T J, Dinkelspiel, H E

“…Ovarian cancer and associated fallopian tube and primary peritoneal cancers fall under a continuum of malignancies arising from the mullerian tract.[...]…”
Get full text

Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers by Contos, G., Baca, Y., Xiu, J., Brown, J., Holloway, R., Korn, W.M., Herzog, T.J., Jones, N., Winer, I.

“…Immuno-oncology (IO) has rapidly evolved, with many IO therapies either approved or under investigation for multiple malignancies. Biomarkers exist that can…”
Get full text

Overview of a chemoresponse assay in ovarian cancer by Grendys, E. C., Fiorica, J. V., Orr, J. W., Holloway, R., Wang, D., Tian, C., Chan, J. K., Herzog, T. J.

“…The objective of this review is to summarize recent scientific and medical literature regarding chemoresponse assays or chemotherapy sensitivity and resistance…”
Get full text

Phase I study of rubitecan and gemcitabine in patients with advanced malignancies by Fracasso, P. M., Rader, J. S., Govindan, R., Herzog, T. J., Arquette, M. A., Denes, A., Mutch, D. G., Picus, J., Tan, B. R., Fears, C. L., Goodner, S. A., Sun, S. L.

“…Background: Rubitecan (9-nitrocamptothecin, 9-NC, Orathecin™) and gemcitabine have single-agent activity in pancreatic and ovarian carcinoma. We conducted a…”
Get full text

Meigs’ syndrome with an elevated CA 125 from benign Brenner tumors by Buttin, Barbara M., Cohn, David E., Herzog, Thomas J.

“…BACKGROUND: Meigs’ syndrome refers to solid, benign ovarian tumors, ascites, hydrothorax, and resolution of these signs after surgery. Meigs’ syndrome with an…”
Get full text

A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer by Hess, L M, Benham-Hutchins, M, Herzog, T J, Hsu, C-H, Malone, D C, Skrepnek, G H, Slack, M K, Alberts, D S

“…Ovarian cancer is the fourth leading cause of cancer death among women in the United States. First-line chemotherapy offered to patients with ovarian cancer…”
Get more information

Lack of Efficacy of 24-h Infusional Topotecan in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Trial by Markman, Maurie, Blessing, John A., DeGeest, Koen, Morgan, Mark, Look, Katherine Y., Herzog, Thomas J., Rose, Peter G.

“…Background. The aim of this study was to evaluate the efficacy of a more convenient topotecan administration schedule in the second-line treatment of advanced…”
Get full text

Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability by Swisher, Elizabeth M., Peiffer‐Schneider, Stacia, Mutch, David G., Herzog, Thomas J., Rader, Janet S., Elbendary, Alaa, Goodfellow, Paul J.

“…BACKGROUND The correlation between tumor microsatellite instability (MSI) and the accumulation of mutations in KRAS2 and TP53 is uncertain. The authors…”
Get full text

Prevalence of Defective DNA Mismatch Repair and MSH6 Mutation in an Unselected Series of Endometrial Cancers by Goodfellow, Paul J., Buttin, Barbara M., Herzog, Thomas J., Rader, Janet S., Gibb, Randall K., Swisher, Elizabeth, Look, Katherine, Walls, Ken C., Fan, Ming-Yu, Mutch, David G.

“…Endometrial cancer is the most common gynecologic malignancy in the United States and the most frequent extracolonic tumor in hereditary nonpolyposis…”
Get full text

Interferon-γ and Tumor Necrosis Factor-α Induce Synergistic Cytolytic Effects in Ovarian Cancer Cell Lines—Roles of the TR60 and TR80 Tumor Necrosis Factor Receptors by Kost, Edward R., Mutch, David G., Herzog, Thomas J.

“…Objective.Utilizing ovarian cancer cell lines, we examined the effect of IFN-γ on each type of TNF receptor. Additionally, we sought to determine the effect of…”
Get full text